Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma

Table 2 Factors associated with overall survival: univariate and multivariate Cox proportional hazards models

Clinicopathologic parameters	Univariate analysis			Multivariate analysis
Clinicopathologic parameters	HR	95% CI	p	HR	95% CI	p
Age (years)
≥ 75 vs. 64–75	1.314	1.069–1.614	0.009	1.156	0.900–1.484	0.256
Gender
Male vs. Female	1.067	0.858–1. 326	0.560
Weight loss
Yes vs. No	0.918	0.747–1. 129	0.419
Chemotherapy
No vs. Yes	1.473	1.199–1. 811	< 0.001	1.405	1.095–1.804	0.007
RT dose (Gy)
≤ 58.8 vs. > 58.8	1.356	1.039–1. 769	0.025	1.185	0.902–1.558	0.223
Tumor location
Cervical/Upper vs. Middle/Lower	0.850	0.674–1. 073	0.171
Tumor length (cm)
> 5.8 vs. ≤ 5.8	1.389	1.129–1. 709	0.002	1.226	0.984–1.528	0.070
Tumor thickness (cm)
> 1.2 vs. ≤ 1.2	1.711	1.369–2.137	< 0.001	1.429	1.126–1.813	0.003
T stage
T4 vs. T2/T3	1.039	0.844–1. 279	0.716
N stage
N2/N3 vs. N0/N1	1.594	1.261–2.015	< 0.001	1.385	1.076–1.784	0.011
TNM stage
Stage III/Stage IV vs. Stage II	1.415	1.102–1.817	0.006	1.217	0.924–1.602	0.162
Year of diagnosis
2007–2017 vs. 2018–2020	1.153	0.873–1.522	0.316
PNI
≤ 41.7 vs. > 41.7	1.669	1.273–2.189	< 0.001	1.227	0.898–1.676	0.199
NLR
> 4.44 vs. ≤ 4.44	1.672	1.226–2.281	0.001	1.135	0.771–1.669	0.521
PLR
> 180 vs. ≤ 180	1.517	1.197–1.924	0.001	1.103	0.818–1.487	0.520
LMR
≤ 3.73 vs. > 3.73	1.357	1.103–1.668	0.004	1.128	0.901–1.413	0.293
SII
> 918 vs. ≤ 918	1.726	1.339–2.226	< 0.001	1.267	0.897–1.790	0.180

HR, hazard ratio; CI, confidence interval; RT, radiotherapy; T, tumor; N, node; TNM, tumor-node-metastasis; PNI, prognostic-nutrition index; NLR, neutrophils-lymphocytes ratio; PLR, platelets-lymphocytes ratio; LMR, lymphocytes-monocytes ratio; SII, systemic immune-inflammation index

ISSN: 1748-717X